Clinical Trials Logo

Metastatic Biliary Tract Cancer clinical trials

View clinical trials related to Metastatic Biliary Tract Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06282120 Recruiting - Clinical trials for Metastatic Biliary Tract Cancer

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this clinical trial is to test in biliary tract cancer patients . The main questions it aims to answer are: - To evaluate the efficacy of irinotecan liposome injection combined with 5-FU/LV± immunotherapy for first-line gemsitabine + immunoprogressive metastatic biliary tract cancer - To evaluate the safety of irinotecan liposome injection combined with 5-FU/LV± immunotherapy for first-line gemsitabine + immunoprogressive metastatic biliary tract cancer This study intends to use liposomal irinotecan combined with 5-FU/LV± immunotherapy for second-line treatment of advanced biliary tract cancer that has progressed after gemsitabine + immunotherapy to evaluate the efficacy and safety of this regimen, with a view to providing better treatment options for second-line patients with advanced biliary tract cancer.

NCT ID: NCT05742750 Not yet recruiting - Clinical trials for Metastatic Biliary Tract Cancer

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Start date: March 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).

NCT ID: NCT03524508 Completed - Clinical trials for Metastatic Biliary Tract Cancer

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Start date: September 4, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of combination of fluorouracil/folinic acid and liposomal irinotecan(Onivyde) compared with fluoruracil/folinic acid in patients with metastatic biliary tract cancer which progressed on 1st line gemcitabine/cisplatin.

NCT ID: NCT02866383 Completed - Clinical trials for Metastatic Pancreatic Cancer

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

CheckPAC
Start date: November 2016
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or BTC refractory or intolerant to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens to determine the efficacy and safety of nivolumab or nivolumab plus ipilimumab administered concurrently with high dose RT. Patients with metastatic PC or BTC who are feasible candidates for radiation and biopsy of primary and/or metastatic lesions will be included.

NCT ID: NCT01096745 Terminated - Clinical trials for Metastatic Biliary Tract Cancer

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy between gemcitabine/cisplatin and S-1/cisplatin in the first-line treatment in advanced biliary tract cancer.